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Abstract 
Review on systemic EBV positive T-cell lymphoma 
of childhood, with data on clinical findings, 
pathology and genetic alterations. 
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Other names 
Systemic EBV-positive T-cell lymphoma of 
childhood has also been termed fulminant EBV-
positive T-cell lymphoproliferative disorder of 
childhood, sporadic fatal infectious mononucleosis, 
fulminant hemophagocytic syndrome in children, 
and fatal EBV-associated hemophagocytic 
syndrome. Use of the term 'severe chronic active 
EBV (severe CAEBV)' is discouraged for this entity. 
Clinics and pathology 
Disease 
Systemic EBV-positive T-cell lymphoma of 
childhood is a rapidly progressive, fatal disease of 
children and young adults characterized by 
monoclonal expansion of EBV-positive T cells with 
an activated cytotoxic phenotype in tissues or 
peripheral blood.  
It has a fulminant clinical course typically associated 
with hemophagocytic syndrome. The prognosis is 
generally poor, and there is no standard treatment, 
although therapy may include allogeneic 
hematopoietic stem cell transplantation. 
Note 
While this review focuses on systemic EBV-positive 
T-cell lymphoma of childhood, EBV infection is 
associated with multiple other non-malignant and 
malignant disorders. For this particular diagnosis, it 
is important to distinguish this type of lymphoma 
from acute self-limited infectious mononucleosis 
with EBV-infected B cells, and the other EBV-
positive lymphoproliferative disorders (LPD) which 
include aggressive NK-cell leukemia, extranodal 
NK/T-cell lymphoma, nasal type, and chronic active 
EBV infection (CAEBV) of T- and NK-cell type 
(cutaneous and systemic forms). It is frequently 
particularly challenging to differentiate systemic 
EBV-positive T-cell lymphoma of childhood from 
acute EBV-associated hemophagocytic 
lymphohistiocytosis (EBV-HLH), and the 
differentiation is often not ultimately made in many 
cases (Coffey et al. 2019; Smith et al. 2014). It is also 
important to distinguish this entity from chronic 
active EBV infection of T- and NK-cell type, which 
can show a broad range of clinical manifestations, 
from indolent, localized forms such as hydroa 
vacciniforme-like lymphoproliferative disorder and 
severe mosquito bite allergy to more systemic 
disease manifestations characterized by symptoms 
similar to systemic EBV-positive T-cell lymphoma 
of childhood. Correlation of morphological, 
immunophenotype and clinical  
features is critical for accurate diagnosis in these 
cases and these disorders may be a biologic 
continuum, rather than discrete entities. 
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Phenotype/cell stem origin 
The cell of origin is thought to be transformed, 
activated cytotoxic T cells. 
Etiology 
Epstein-Barr virus (EBV) is a herpesvirus with a 
double-stranded DNA genome. EBV was first 
discovered from cells isolated from African patients 
with Burkitt's lymphoma and was later recognized to 
be highly prevalent worldwide (Epstein et al. 1964), 
causing chronic latent infection with lifelong 
persistence in more than 90% of the world's 
population. EBV has been linked to several 
malignancies, including nasopharyngeal carcinoma, 
gastric carcinoma and 
lymphomas/lymphoproliferative diseases including 
Burkitt lymphoma, classical Hodgkin lymphoma, 
post-transplantation lymphoproliferative disorders, 
NK/T cell lymphoma (nasal type), aggressive NK-
cell leukemia, angioimmunoblastic T cell 
lymphoma.  It is thought that these disorders arise 
due to impaired balance between the host immune 
response and EBV virus.  Given the racial 
predispositions to some of these disorders, including 
systemic EBV-positive T-cell lymphoma of 
childhood, it is postulated that there may be genetic 
defects in host immune responses to EBV that 
increase susceptibility to transformation. 
Additionally, there are genetically different strains 
of EBV, which may have different propensities for 
contributing to cancer development (Rickinson et al. 
1987; Yakovleva et al. 2015). 
Epidemiology 
Systemic EBV-positive T-cell lymphoma of 
childhood is extremely rare but reports of this 
disease have most frequently been in Asians 
including individuals from Japan and China (Kikuta 
et al. 1993; Su et al. 1994; Suzuki et al. 2004; Yoshii 
et al. 2012; Zhu et al. 2019). Additional reports have 
described the disorder in several individuals from 
Mexico, Central and South America, and occasional 
individuals whose ethnic origin is described as 
White, not further specified (Coffey et al. 2019; 
Quintanilla-Martinez et al. 2000). It occurs most 
often in children and young adults. 
Clinics 
The disease usually occurs in previously healthy 
children or adolescents shortly after acute primary 
EBV infection; however, it has also been described 
as an evolution from chronic active EBV infection. 
While reports of the disease are rare, accumulated 
data from several individual patients suggests that 
the disease generally develops within days to weeks 
of infectious mononucleosis symptoms. Patients 
progress to increasing malaise, high fever, 
hepatosplenomegaly, and jaundice with or without 
minimal lymphadenopathy.  
High EBV viral loads, and elevated liver enzymes 
are common.  In serological tests for EBV, IgM 
antibodies against the viral capsid antigen (VCA) are 
often low to absent in the majority of patients; yet 
IgG antibodies against VCA are often positive 
(Kikuta et al., 1993). Pancytopenia and 
coagulopathies have also been reported in several of 
the patients. Similarly, fever, hepatosplenomegaly, 
and frequent lymphadenopathy are also present in 
reported cases arising from patients with CAEBV. 
(Coffey et al. 2019; Kikuta et al. 1993; Quintanilla-
Martinez et al. 2000; Zhu et al. 2019). Patients in 
either group generally develop hemophagocytic 
lymphohistiocytosis, sepsis, and multiorgan 
dysfunction, which ultimately lead to death usually 
within days to weeks. 
Cytology 
The lymphocytes in this disorder are generally 
described as small and lacking significant atypia 
(Quintanilla-Martinez et al. 2000). Some cases are 
reported to show atypical pleomorphic medium to 
large-sized lymphoid cells (Hong et al. 2013; Yoshii 
et al. 2012). Findings of cytologic atypia, if present, 
may be indistinguishable from those of infectious 
mononucleosis. 
Pathology 
By morphology, there is an increase in small 
lymphoid cells and histiocytes, usually accompanied 
by hemophagocytosis in the liver, spleen, lymph 
nodes, and bone marrow. Skin and lungs may also be 
involved.  
Bone marrow biopsies tend to show histiocytic 
hyperplasia, prominent hemophagocytosis, and  an 
interstitial lymphocytic infiltrate (Figure 1). (Coffey 
et al. 2019; Quintanilla-Martinez et al. 2000).  
Multiple reports describe lymph nodes as being 
largely unremarkable with preserved architecture 
and open sinuses, although occasional cases have 
been described to have partial or more complete 
destruction with paracortical expansion by a 
prominent infiltration of small to medium-size 
atypical lymphocytes and areas of necrosis (Coffey 
et al. 2019; Hong et al. 2013; Quintanilla-Martinez 
et al. 2000; Zhu et al. 2019). Variable sinus 
histiocytosis with erythrophagocytosis has been 
described.  
The liver in reported cases demonstrates infiltration 
of small lymphocytes in portal, lobular, and 
sinusoidal areas.  
Cholestasis, steatosis, hepatocyte necrosis, and 
hemophagocytosis can also be seen (Figure 2) 
(Coffey et al. 2019; Quintanilla-Martinez et al. 2000, 
Yoshii et al. 2012).   
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Figure 1:  Bone marrow biopsy from a patient diagnosed with systemic EBV-positive T-cell lymphoma of childhood.  (A)  
Numerous scattered intermediate and large sized atypical lymphoid cells and histiocytes with decreased background 
hematopoiesis. The atypical lymphoid cells are positive for (B) CD8 and  (C)  EBER.  (D)  CD163 highlights numerous 
macrophages, some with hemophagocytosis. 
 
 
 
Figure 2:  At autopsy, the liver of this 3 year old with systemic EBV positive T-cell lymphoma demonstrated  (A)  multiple mass 
forming vasculocentric foci of necrosis (right in photomicrograph) with interspersed atypical lymphocytes at the junction of viable 
and necrotic liver.  (B)  These atypical lymphocytes expressed EBV by EBER in situ hybridization. 
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The spleen can show inconspicuous to markedly 
depleted white pulp, with a prominent lymphoid 
infiltration and hemophagocytosis in the splenic 
sinusoids and occasionally necrosis (Quintanilla-
Martinez et al. 2000). 
Cytogenetics 
No consistent chromosomal aberrations have been 
identified, although cases with chromosomal 
aberrations are generally fatal (Smith et al. 2014). 
The finding of chromosomal aberrations has been 
suggested as a feature to support a diagnosis of 
systemic EBV-positive T-cell lymphoma of 
childhood over EBV-HLH (Kim et al. 2019). 
Genes 
he infiltrating T lymphocytes show monoclonal 
rearrangements of the TCR genes, although notably 
this can also been seen in about half of EBV-HLH 
cases (Coffey et al. 2019; Kim et al. 2019; Yoshii et 
al, 2012). All cases of systemic EBV-positive T-cell 
lymphoma of childhood harbour EBV in a clonal, 
episomal form (Jones et al. 1988; Kikuta et al. 1993; 
Suzuki et al. 2004). 
Treatment 
At present, there is no effective, standard treatment. 
CHOP-like regimens or immunosuppressive 
therapies are options, but most patients experience 
recurrence. Few cases have been reported to respond 
to an etoposide- and dexamethasone-based regimen 
typically used for HLH (Coffey et al. 2019; Smith et 
al. 2014).  Additionally, treatment with SMILE 
regimen (dexamethasone, methotrexate, ifosfamide, 
L-asparaginase, and etoposide) has been reported in 
rare patients (Yoshida et al. 2017).  The ultimate goal 
is to get the patients to allogeneic hematopoietic 
stem cell transplantation (Coffey et al. 2019). 
Evolution 
The disease usually occurs shortly after acute 
primary EBV infection in previously healthy 
children or adolescents but has also been described 
evolving from a multi-year long course of chronic 
active EBV infection. 
Prognosis 
The prognosis is poor with a generally fulminant 
clinical course with most patients succumbing to the 
disease within days to weeks. The disease is usually 
complicated by hemophagocytic syndrome. 
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